Argenx delivers on promise to transform patient expectations in autoimmunity at american academy of neurology 2024 annual meeting

Adhere data presentation will highlight first potential innovation for cidp patients in 30 years abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of vyvgart® and vyvgart® hytrulo in gmg patients march 7, 2024, 10:01 pm cet amsterdam, the netherlands   – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that eight abstracts, including two oral presentations, featuring clinical trial and real-world data for vyvgart (efgartigimod alfa-fcab) and vyvgart hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in rare autoimmune diseases will be presented at the american academy of neurology (aan) annual meeting, taking place in denver, co from april 13-18, 2024. “we are opening a new chapter for the vyvgart portfolio,” said luc truyen, m.d.
ARGX Ratings Summary
ARGX Quant Ranking